알레르기성 결막염 시장 : 인사이트, 역학, 시장 예측(-2034년)

Key Highlights:

• The rising prevalence of allergic conjunctivitis is linked to increasing air pollution, climate change, and higher exposure to allergens like pollen, dust mites, and pet dander. Urbanization, lifestyle changes, and prolonged screen time also weaken ocular immunity. Additionally, greater awareness and improved diagnosis contribute to more reported cases, making allergic conjunctivitis a growing public health concern.
• The allergic conjunctivitis market is becoming increasingly competitive with the approval of innovative therapies such as DEXTENZA and ALESION Eyelid Cream 0.5%. These advanced treatment options are gaining market traction, intensifying competition among pharmaceutical companies and driving the development of more effective, targeted, and convenient solutions for patients.
• The allergic conjunctivitis market is on a growth trajectory, with companies such as Aldeyra Therapeutics actively progressing their pipeline candidates through key development phases. As several therapies approach potential regulatory approvals within the 2025-2034 forecast window, the therapeutic landscape is expected to expand considerably, fueled by a strong compound annual growth rate (CAGR).
• In May 2024, Santen Pharmaceutical and Mitsubishi Tanabe Pharma announced the conclusion of agreement to jointly promote ALESION Eyelid Cream 0.5% in Japan, marking a collaborative effort to advance the market reach of this new treatment for allergic conjunctivitis.

DelveInsight's comprehensive report titled "Allergic Conjunctivitis - Market Insights, Epidemiology, and Market Forecast - 2034" offers a detailed analysis of allergic conjunctivitis. The report presents historical and projected epidemiological data covering Diagnosed Prevalent Cases of Allergic Conjunctivitis, Type-specific Diagnosed Prevalent Cases of Allergic Conjunctivitis, and Age-specific Diagnosed Prevalent Cases of Allergic Conjunctivitis. In addition to epidemiology, the market report encompasses various aspects related to the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2020 to 2034.

The report analyzes the existing treatment practices and unmet medical requirements in allergic conjunctivitis. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.

Allergic Conjunctivitis Overview

Allergic conjunctivitis, also known as ocular allergy, is a common inflammatory condition of the conjunctiva-the transparent membrane covering the white part of the eye-caused by allergic reactions. This immune response is typically mediated by Immunoglobulin E (IgE), where direct exposure to allergens in sensitized individuals triggers mast cell activation and the release of inflammatory chemicals. The condition usually affects both eyes and is self-limiting. In 2006, the International Ocular Inflammation Society classified AC into six types based on their underlying immune mechanisms and clinical characteristics: seasonal allergic conjunctivitis (SAC), perennial allergic conjunctivitis (PAC), atopic keratoconjunctivitis (AKC), vernal keratoconjunctivitis (VKC), giant papillary conjunctivitis (GPC), and contact dermatoconjunctivitis (CDC). Each subtype presents differently, varies in severity, and responds differently to treatment. Allergic conjunctivitis often coexists with other allergic diseases such as asthma, atopic dermatitis, or food allergies, and it is particularly associated with allergic rhinitis. When symptoms of Allergic conjunctivitis and allergic rhinitis appear together, the combined condition is referred to as rhinoconjunctivitis, which can complicate the understanding and management of each disorder on its own.

Allergic Conjunctivitis Diagnosis and Treatment Overview

Diagnosis of allergic conjunctivitis is primarily clinical, relying on the patient's history and hallmark symptoms such as itchy, red, watery eyes often accompanied by eyelid swelling and burning. A slit-lamp examination may reveal classic signs like conjunctival redness, chemosis, and papillary hypertrophy. While not always required, allergy testing-such as skin prick tests or serum-specific IgE assays-can help identify triggering allergens. Treatment focuses on symptom relief and allergen avoidance. First-line strategies include avoiding known allergens, using cold compresses, and applying preservative-free artificial tears to flush irritants. Pharmacological options include topical antihistamines, mast cell stabilizers, and combination agents offering both rapid and sustained relief. In more severe cases, short-term use of topical corticosteroids may be prescribed, while oral antihistamines can help when systemic allergy symptoms are present. For patients with persistent or severe allergies, allergen-specific immunotherapy may offer long-term benefits by desensitizing the immune system to the offending agents.

Allergic Conjunctivitis Epidemiology

The epidemiology section of the allergic conjunctivitis market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.

This section also presents the data with relevant tables and graphs, offering a clear and concise view of the prevalence of allergic conjunctivitis. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.

Key Findings

• Based on secondary data analysis in US, approximately 40% of individuals aged over 17 years exhibited ocular allergic symptoms, leading to their classification under allergic conjunctivitis.
• According to the study findings, seasonal and perennial allergic conjunctivitis represent the most dominant forms of ocular allergy in the US, collectively accounting for over 95% of all diagnosed cases.
• Based on secondary analysis, the prevalence of SAC in Italy was reported to be 55%.
• As per the study conducted in Japan, it reveals that allergic conjunctivitis prevalence increases progressively from childhood through mid-adulthood, peaking at 28.1% in individuals aged 40-44 years. This trend suggests a correlation between allergen exposure, sensitization, and age. Prevalence subsequently declines in older populations, with markedly lower rates observed in individuals aged 70 and above.
• According to secondary analysis conducted in Japan, allergic conjunctival disorders demonstrated varied prevalence among affected individuals. SAC emerged as the most predominant subtype, accounting for 45.4% of the reported cases. This was followed by PAC, which affected 14.0% of individuals. Less commonly observed were atopic keratoconjunctivitis and vernal keratoconjunctivitis, comprising 5.3% and 1.2% of cases, respectively.

Allergic Conjunctivitis Market Outlook

The allergic conjunctivitis therapeutics market is further expected to increase by the major drivers, such as the rising prevalent population, technological advancements, and upcoming therapies in the forecast period [2025-2034].

The treatment of allergic conjunctivitis aims to alleviate symptoms such as itching, redness, and tearing while controlling underlying inflammation and preventing recurrence. First-line therapies often include antihistamine or dual-action eye drops that offer rapid relief. Mast cell stabilizers are useful for long-term control, while corticosteroids like loteprednol or the DEXTENZA insert may be used short-term in severe cases. Newer options like ALESION Eyelid Cream provide targeted relief with convenient once-daily application. Supportive measures-such as artificial tears, cold compresses, and allergen avoidance-enhance symptom management. Treatment is typically personalized based on symptom severity, chronicity, and patient response to therapy.

With ongoing research and continued dedication, the future holds hope for even more effective treatments and, ultimately, a cure for this challenging condition. According to DelveInsight, the Allergic Conjunctivitis market in the 7MM is expected to change significantly during the study period 2020-2034.

Allergic Conjunctivitis Drug Chapters

Marketed Drugs

DEXTENZA (Dexamethasone): Ocular Therapeutix

DEXTENZA is a corticosteroid intracanalicular insert designed to treat post-surgical eye inflammation and pain, as well as itching caused by allergic conjunctivitis. It is placed into the lower lacrimal punctum, where it resides in the canaliculus and gradually delivers 0.4 mg of dexamethasone over a period of up to 30 days. The insert is fully resorbable and does not require removal.

• In October 2021, Ocular Therapeutix announced that the US FDA had approved its Supplemental New Drug Application (sNDA), expanding the DEXTENZA label to include a new indication for treating ocular itching related to allergic conjunctivitis.

ALESION Eyelid Cream 0.5%: Santen Pharmaceutical

ALESION Cream contains epinastine hydrochloride, a histamine H1 receptor antagonist originally discovered and developed by Boehringer Ingelheim. It works by inhibiting the release of chemical mediators from mast cells. It is world's first topical treatment for allergic conjunctivitis in cream form, designed for once-daily application to both the upper and lower eyelids, targeting the periocular area effectively with minimal dosing frequency.

• In a Phase III Conjunctival Allergen Challenge trial conducted in Japan-randomized, double-masked, and placebo-controlled-the cream demonstrated significant efficacy during the asymptomatic phase. It showed clear superiority over a placebo eyelid cream in alleviating pruritus and conjunctival hyperemia, the hallmark symptoms of allergic conjunctivitis.
• In May 2024, Santen Pharmaceutical Co. and Mitsubishi Tanabe Pharma Corporation announced the commercial launch of ALESION Eyelid Cream 0.5% in Japan, introducing it as a new therapeutic option for the treatment of allergic conjunctivitis.

Emerging Allergic Conjunctivitis Drugs

The Allergic Conjunctivitis market is expected to experience gradual changes, mainly due to the limited availability of emerging therapies in this area. Key market players, including, Aldeyra Therapeutics' Reproxalap, among others, have demonstrated a keen interest in this condition and are actively pursuing the development of potential treatments.

Reproxalap: Aldeyra Therapeutics

Reproxalap is a novel, small-molecule inhibitor of reactive aldehyde species (RASP) developed by Aldeyra Therapeutics. It is administered topically and is being investigated for the treatment of allergic conjunctivitis. Clinical trials have shown that reproxalap is safe, well-tolerated, and effective in reducing ocular discomfort, redness, itching, and tearing by modulating inflammatory pathways in the eye.

• In November 2023, Aldeyra Therapeutics signed an exclusive option agreement with AbbVie for reproxalap. The deal grants AbbVie rights to co-develop and commercialize the drug in the US and exclusive rights outside the US. Aldeyra received a USD 1 million option fee and would receive USD 100 million upfront if AbbVie exercises the option.
• In the Phase III ALLEVIATE clinical trial involving patients with allergic conjunctivitis, both the primary and key secondary endpoints were successfully met. Treatment with reproxalap resulted in a significant reduction in ocular itch scores and demonstrated clinically meaningful improvements in patient outcomes.

Allergic Conjunctivitis Market Segmentation

DelveInsight's 'Allergic Conjunctivitis - Market Insights, Epidemiology, and Market Forecast - 2034' report provides a detailed outlook of the current and future allergic conjunctivitis market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.

Allergic Conjunctivitis Market Size by Countries

The allergic conjunctivitis market size is assessed separately for various countries, including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. In 2024, the United States held a significant share of the overall 7MM (Seven Major Markets) allergic conjunctivitis market, primarily attributed to the country's higher prevalence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.

Allergic Conjunctivitis Drugs Uptake

This section focuses on the sales uptake of potential allergic conjunctivitis drugs that have recently been launched or are anticipated to be launched in the allergic conjunctivitis market between 2020 and 2034. It estimates the market penetration of allergic conjunctivitis drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the allergic conjunctivitis market.

The emerging allergic conjunctivitis therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the allergic conjunctivitis market.

Allergic Conjunctivitis Market Access and Reimbursement

DelveInsight's 'Allergic Conjunctivitis - Market Insights, Epidemiology, and Market Forecast - 2034' report provides a descriptive overview of the market access and reimbursement scenario of allergic conjunctivitis.

This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.

KOL Views

To keep up with current allergic conjunctivitis market trends and fill gaps in secondary findings, we interview KOLs and SMEs' working in the allergic conjunctivitis domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or allergic conjunctivitis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the allergic conjunctivitis unmet needs.

Allergic Conjunctivitis: KOL Insights

DelveInsight's analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as Memorial Sloan Kettering Cancer Center, US, Stanford University School of Medicine, US, Royal Devon and Exeter Hospital, UK, Hospital Clinico San Carlos de Madrid Department of Ophthalmology, Madrid, Spain, Tottori University, Tottori, Japan among others.

"Despite available therapies, allergic conjunctivitis still presents unmet needs: many treatments offer only short-term relief, require frequent dosing, or inadequately manage chronic symptoms. Long-term steroid use poses safety risks, highlighting the need for innovative, well-tolerated, and long-acting treatments that effectively address inflammation, improve adherence, and enhance patient quality of life."

"Allergic conjunctivitis is a growing public health concern impacting both children and adults, leading to marked reductions in quality of life. In some cases, particularly when left untreated or poorly managed, it may also result in irreversible visual impairment."

"Asia ranks among the regions with the highest burden of allergic conjunctival diseases. Within this context, Japan stands out as a significant hotspot, exhibiting notably high prevalence rates. Moreover, Japan provides a wealth of comprehensive data, enabling detailed analysis of the environmental factors influencing disease occurrence and distribution."

Competitive Intelligence Analysis

We conduct a Competitive and Market Intelligence analysis of the Allergic Conjunctivitis. Market, utilizing various Competitive Intelligence tools such as SWOT analysis and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.

Allergic Conjunctivitis Pipeline Development Activities

The report offers an analysis of therapeutic candidates in Phase II and III stages and examines companies involved in developing targeted therapeutics for allergic conjunctivitis. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.

Pipeline Development Activities

The report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging allergic conjunctivitis therapies.

Allergic Conjunctivitis Report Insights

• Allergic Conjunctivitis Patient Population
• Therapeutic Approaches
• Allergic Conjunctivitis Pipeline Analysis
• Allergic Conjunctivitis Market Size and Trends
• Allergic Conjunctivitis Market Opportunities
• Impact of Upcoming Therapies

Allergic Conjunctivitis Report Key Strengths

• 10 Years Forecast
• The 7MM Coverage
• Allergic Conjunctivitis Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Allergic Conjunctivitis Market
• Allergic Conjunctivitis Drugs Uptake

Allergic Conjunctivitis Report Assessment

• Allergic Conjunctivitis Current Treatment Practices
• Unmet Needs
• Allergic Conjunctivitis Product Profiles
• Allergic Conjunctivitis Market Attractiveness

Key Questions:

• How common is allergic conjunctivitis?
• What are the key findings of allergic conjunctivitis epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2020-2034)?
• What are the currently available treatments for allergic conjunctivitis?
• What are the disease risk, burden, and unmet needs of allergic conjunctivitis?
• At what CAGR is the allergic conjunctivitis market and its epidemiology is expected to grow in the 7MM during the forecast period (2025-2034)?
• How would the unmet needs impact the allergic conjunctivitis market dynamics and subsequently influence the analysis of the related trends?
• What would be the forecasted patient pool of allergic conjunctivitis in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2025-2034)?
• How many companies are currently developing therapies for the treatment of allergic conjunctivitis?

Reasons to buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the allergic conjunctivitis market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of current treatment in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the attribute analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Frequently Asked Questions:

1. What are the treatment goals for allergic conjunctivitis?

The primary treatment goals for allergic conjunctivitis are to relieve ocular symptoms such as itching, redness, tearing, and swelling, while minimizing inflammation and preventing disease progression or recurrence. Effective therapy aims to improve visual comfort and overall quality of life. In chronic or severe cases, long-term control is key, along with avoiding allergen exposure and reducing the need for corticosteroids through safer, targeted medications.

2. What are the challenges in managing allergic conjunctivitis?

Managing allergic conjunctivitis presents several challenges, including underdiagnosis, frequent symptom recurrence, and limited long-term treatment options. Many therapies require multiple daily doses, affecting adherence. Chronic cases may need corticosteroids, which pose safety concerns with prolonged use. Environmental triggers like pollen and pollution further complicate control. Additionally, coexisting conditions such as dry eye disease can exacerbate symptoms, making comprehensive and individualized management essential for effective care.

3. What are the key factors driving the growth of the allergic conjunctivitis market?

The growth of the allergic conjunctivitis market is driven by rising global prevalence of allergic conditions, increasing environmental pollution, and heightened exposure to allergens. Advancements in ophthalmic drug formulations, growing awareness of ocular allergies, and the shift of certain therapies from prescription to over-the-counter status further fuel demand. Additionally, increased healthcare spending and the development of novel, long-acting treatments contribute to expanding market opportunities.

4. How will the Allergic Conjunctivitis Market and Epidemiology Forecast Report benefit the clients?

The Allergic Conjunctivitis Market and Epidemiology Forecast Report will benefit clients by providing comprehensive insights into market trends, treatment options, patient populations, and future growth opportunities, helping them make informed strategic decisions and identify potential areas for investment or expansion.

Table of Contents

1. Key Insights

2. Report Introduction

3. Market Overview at a Glance

• 3.1. Market Share (%) Distribution of Allergic Conjunctivitis in 2020
• 3.2. Market Share (%) Distribution of Allergic Conjunctivitis by 2034

4. Epidemiology and Market Methodology

5. Executive Summary

6. Key Events

7. Disease Background and Overview

• 7.1. Introduction
• 7.2. Types
• 7.3. Causes
• 7.4. Pathophysiology
• 7.5. Symptoms
• 7.6. Risk Factor
• 7.7. Diagnosis
  • 7.7.1. Diagnostic Algorithm
  • 7.7.2. Diagnostic Guidelines
• 7.8. Treatment and Management
  • 7.8.1. Treatment Algorithm
  • 7.8.2. Treatment Guidelines

8. Epidemiology and Patient Population

• 8.1. Key Findings
• 8.2. Assumptions and Rationale:7MM
• 8.3. Diagnosed Prevalent Cases of Allergic Conjunctivitis in the 7MM
• 8.4. The United States
  • 8.4.1. Diagnosed Prevalent Cases of Allergic Conjunctivitis
  • 8.4.2. Type-specific Diagnosed Prevalent Cases of Allergic Conjunctivitis
  • 8.4.3. Age-specific Diagnosed Prevalent Cases of Allergic Conjunctivitis
• 8.5. EU4 and the UK
  • 8.5.1. Diagnosed Prevalent Cases of Allergic Conjunctivitis
  • 8.5.2. Type-specific Diagnosed Prevalent Cases of Allergic Conjunctivitis
  • 8.5.3. Age-specific Diagnosed Prevalent Cases of Allergic Conjunctivitis
• 8.6. Japan
  • 8.6.1. Diagnosed Prevalent Cases of Allergic Conjunctivitis
  • 8.6.2. Type-specific Diagnosed Prevalent Cases of Allergic Conjunctivitis
  • 8.6.3. Age-specific Diagnosed Prevalent Cases of Allergic Conjunctivitis

9. Patient Journey

10. Marketed Therapies

• 10.1. DEXTENZA (Dexamethasone): Ocular Therapeutix
  • 10.1.1. Product Description
  • 10.1.2. Regulatory Milestone
  • 10.1.3. Other Development Activities
  • 10.1.4. Clinical Trials Information
  • 10.1.5. Safety and Efficacy
• 10.2. ALESION Eyelid Cream 0.5%: Santen Pharmaceutical
  • 10.2.1. Product Description
  • 10.2.2. Regulatory Milestone
  • 10.2.3. Other Development Activities
  • 10.2.4. Clinical Trials Information
  • 10.2.5. Safety and Efficacy

The list will be continued in the report...

11. Emerging Therapies

• 11.1. Key Cross Competition
• 11.2. Reproxalap: Aldeyra Therapeutics
  • 11.2.1. Drug Description
  • 11.2.2. Other Development Activities
  • 11.2.3. Clinical Trials Information
  • 11.2.4. Safety and Efficacy
  • 11.2.5. Analyst View

The list will be continued in the report...

12. Allergic Conjunctivitis : Seven Major Market Analysis

• 12.1. Key Findings
• 12.2. Market Outlook
• 12.3. Attribute Analysis
• 12.4. Key Market Forecast Assumptions
  • 12.4.1. Cost Assumptions and Rebates
  • 12.4.2. Pricing Trends
  • 12.4.3. Analogue Assessment
  • 12.4.4. Launch Year and Therapy Uptake
• 12.5. Total Market Size of Allergic Conjunctivitis in the 7MM
• 12.6. Market Size of Allergic Conjunctivitis by Therapies in the 7MM
• 12.7. The United States Market Size
  • 12.7.1. Total Market Size of Allergic Conjunctivitis
  • 12.7.2. Market Size of Allergic Conjunctivitis by Therapies
• 12.8. EU4 and the UK Market Size
  • 12.8.1. Total Market Size of Allergic Conjunctivitis
  • 12.8.2. Market Size of Allergic Conjunctivitis by Therapies
• 12.9. Japan Market Size
  • 12.9.1. Total Market Size of Allergic Conjunctivitis
  • 12.9.2. Market Size of Allergic Conjunctivitis by Therapies

13. Key Opinion Leaders' Views

14. Unmet Needs

15. SWOT Analysis

16. Market Access and Reimbursement

17. Appendix

• 17.1. Bibliography
• 17.2. Abbreviations and Acronyms
• 17.3. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight